<DOC>
	<DOC>NCT02384317</DOC>
	<brief_summary>This is a pilot study to test safety, tolerability, and efficacy of CCX168 in reducing proteinuria in patients with Immunoglobulin A nephropathy and persistent proteinuria despite supportive therapy with a maximally tolerated RAAS blocker.</brief_summary>
	<brief_title>Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin A</mesh_term>
	<criteria>Key Diagnosis of Immunoglobulin A nephropathy estimated glomerular filtration rate &gt;60 mL/min/1.73 m2 Proteinuria (first morning urinary protein:creatinine ratio &gt;1g/g creatinine) Key Severe renal disease Pregnant or nursing Proteinuria &gt;8g/g creatinine or &gt;8g/day Systemic manifestations of HenochSchonlein purpura within 2 years prior Patients with Immunoglobulin A nephropathy deemed secondary to underlying disease Biopsy reported severe crescentic Immunoglobulin A nephropathy History of treatment with glucocorticoids, cyclophosphamide, azathioprine, mycophenolate mofetil, or any biologic immunomodulatory agent with 24 weeks prior History of clinically significant cardiac conditions History of cancer within 5 years prior Any infection requiring antibiotic treatment that has not cleared prior to study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>